Login to Your Account



Pfizer inks new GKA development deal with China's Pegbio

By Pearl Liu
Staff Writer

Friday, January 6, 2017

HONG KONG – Pfizer Inc. will partner with Suzhou-based Pegbio Co. Ltd. to develop glucokinase activator drugs for China as part of the multinational's strategy of using local partners to further the development of innovative drugs that address unmet needs in China.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription